Stockreport

Centessa Pharmaceuticals CEO Touts ORX750 as Best-in-Class as Registration Studies Nearing Start [Yahoo! Finance]

Centessa Pharmaceuticals plc - American Depositary Shares  (CNTA) 
PDF ORX750 Phase 2 early cohorts showed promising signals — 20-minute placebo-adjusted MWT improvement in NT1 (1.5 mg) with ESS dropping 18?5 and an 87% cataplexy reduction [Read more]